Industries
What "quality" means is defined by what happens when you fail.
A bad release costs revenue per minute in e-commerce. In fintech it costs money and then a regulator asks why. In pharma it becomes a finding in an inspection. Same engineering discipline, entirely different risk calculus, evidence requirements, and definition of done.
That difference is not a matter of domain vocabulary. It changes what you test first, how much evidence you keep, and who signs off.
Fintech & Financial Services
When it failsMoney moves incorrectly, and someone with statutory authority asks you to explain how.
What that demandsTransaction and reconciliation coverage, data integrity under concurrency, audit trails that survive review, and evidence produced as a by-product of testing rather than assembled afterward.
- 60%faster test design
- 35%more coverage
- 40%less manual effort
Healthcare & HealthTech
When it failsClinical decisions get made on data that isn't right, and the failure is invisible until it isn't.
What that demandsRequirement traceability from clinical intent to test result, PHI handling under HIPAA, and interoperability testing across systems you don't control.
- 50%faster requirement analysis
- 45%fewer requirement defects
- 100%traceability
Pharma
When it failsData integrity is challenged during an inspection, and remediation costs more than the original project.
What that demandsValidation under 21 CFR Part 11 — electronic records, electronic signatures, audit trails, and ALCOA+ data integrity, with documentation that stands up to an auditor rather than a stakeholder.
Pharma validationWe validate pharma software products against 21 CFR Part 11.
Part 11 is our scope — electronic records, signatures, audit trail, data integrity. We'll tell you plainly where a programme needs capability we don't have rather than learn it on your validation.
E-commerce & SaaS
When it failsRevenue stops, and conversion dies quietly for hours before anyone notices.
What that demandsCheckout and subscription path coverage, behaviour under peak load, third-party integrations you can't control, and release confidence at a cadence that doesn't allow a two-week regression cycle.
- 90%accuracy in release-readiness prediction
- 90%time saved on reporting
Communications
When it failsThe defect is service-affecting, it reaches a large population at once, and the same class of defect returns next quarter.
What that demandsRoot cause analysis that actually closes the loop, defect trend intelligence, and testing across a stack where new services sit on infrastructure older than the team.
- 55%faster root cause identification
- 40%reduction in repeat defects
Does QA differ by industry?
The risk model changes. The engineering doesn't.
Every engagement runs on the same operating model — the AI-Native Delivery Framework — and is measured against the same AI Maturity Model. What the industry determines is where you start, what evidence you retain, and which failures are unacceptable rather than merely expensive.
A vendor whose method changes completely by sector doesn't have a method.
Where we're not the right fit
Safety-critical embedded systems. DO-178C and ISO 26262 programmes need specialists we aren't.
Volume staffing. If you need twenty testers next month, we're a small senior team and we'll say so on the first call.
Telling you what we're wrong for is cheaper for both of us than discovering it in month two.
Not sure which of these describes you, or you're in none of them?
The engineering is the same. Book a call and we'll tell you honestly whether we're a fit.